![]() Do not stop taking TRUVADA without your doctor's advice. If you are also infected with the Hepatitis B Virus, “flare-ups” of Hepatitis B Virus infection, in which the disease suddenly returns in a worse way than before, can occur if you stop taking TRUVADA.Your doctor may need to perform additional blood tests if you have had kidney problems in the past or need to take another drug that can cause kidney problems. Some patients treated with tenofovir disoproxil fumarate (a component of TRUVADA ) have had kidney problems. Your doctor may monitor your kidney function before beginning and while receiving TRUVADA. The most serious possible side effect is harm to the kidneys, including damage to kidney cells, kidney tissue inflammation and kidney failure.Call your doctor or pharmacist if you are not sure what to do. Do not take more than 1 dose of TRUVADA in a day. If more than 12 hours has passed from the time you usually take TRUVADA, then wait until the next scheduled daily dose. If you miss a dose of TRUVADA and it is less than 12 hours from the time you usually take TRUVADA, then take the dose. It is important that you do not miss any doses. In case of drug overdose, contact a healthcare practitioner, hospital emergency department or regional poison control centre, even if there are no symptoms. The usual dose of TRUVADA is one tablet orally (by mouth) once a day.TRUVADA may be taken with or without a meal.įor prevention of HIV-1 infection (PrEP):.The usual dose of TRUVADA is one tablet orally (by mouth) once a day, in combination with other anti-HIV medicines.Do not give TRUVADA to others or take medicine prescribed for someone else.ĭo not use if seal over bottle opening is broken or missing. Only take medicine that has been prescribed specifically for you. The virus may develop resistance to TRUVADA and become harder to treat. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. When your TRUVADA supply starts to run low, get more from your doctor or pharmacy. Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vagina secretions, or blood.Īsk your healthcare provider if you have any questions on how to prevent getting HIV infection or spreading HIV infection to other people. Do not have any kind of sex without protection.Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.Do not re-use or share needles or other injection equipment.take TRUVADA every day, not just when you think you have been exposed to HIV-1.Īvoid doing things that can increase your risk of getting HIV infection or spreading HIV infection to other people:. ![]() you must also use other methods to reduce your risk of getting HIV.If you take TRUVADA to reduce your risk of getting HIV-1: When used to treat HIV-1 infection, TRUVADA is always used with other HIV-1 medicines. Set up a dosing schedule and follow it carefully. Follow the directions from your doctor, exactly as written on the label. Take TRUVADA exactly as your doctor prescribed it. Do not change your treatment or stop treatment without first talking with your doctor. 3:19-cv-02573, 6/30/23.Stay under a doctor's care when taking TRUVADA. The case is In re HIV Antitrust Litigation, N.D. Teva didn’t immediately respond to a request for comment. The companies’ agreement resulted in higher prices for the HIV drugs, plaintiffs claimed.īut the verdict affirmed that the companies’ settlement “was not a reverse payment,” Gilead said in a Friday statement. In reverse payments, a patent-owner company pays an alleged patent infringer, typically a generic drugmaker, to delay selling the generic version. Gilead allegedly paid Teva, a generic drugmaker, a “reverse payment” worth $1 billion in a patent settlement to shelve Teva’s generic versions of Truvada and another similar drug, the lawsuit claimed. Plaintiffs sought $3.6 billion in damages. The unanimous verdict Friday from the US District Court for the Northern District of California affirmed that a 2014 patent settlement between Foster City, Calif.-based Gilead and Israel-based Teva didn’t violate antitrust law.Ĭonsumers and other direct purchasers, including the Blue Cross and Blue Shield Association, filed the antitrust lawsuit in 2019, alleging that Gilead maintained a monopoly in the HIV drug market by unlawfully extending patent protection for its drugs to delay generic competitors’ entry. didn’t engage in an anticompetitive conspiracy to delay generic versions of HIV treatment Truvada and other drugs. A California jury found that Gilead Sciences Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |